Hemagen Diagnostics Stock Current Valuation
| HMGNDelisted Stock | USD 0.0001 0.00 0.00% |
Valuation analysis of Hemagen Diagnostics helps investors to measure Hemagen Diagnostics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Hemagen Diagnostics' price fluctuation is very steady at this time. Calculation of the real value of Hemagen Diagnostics is based on 3 months time horizon. Increasing Hemagen Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Hemagen Diagnostics is useful when determining the fair value of the Hemagen pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of Hemagen Diagnostics. Since Hemagen Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Hemagen Pink Sheet. However, Hemagen Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.5E-5 | Hype 1.0E-4 | Naive 1.0E-4 |
The real value of Hemagen Pink Sheet, also known as its intrinsic value, is the underlying worth of Hemagen Diagnostics Company, which is reflected in its stock price. It is based on Hemagen Diagnostics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Hemagen Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Hemagen Diagnostics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Hemagen Diagnostics helps investors to forecast how Hemagen pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Hemagen Diagnostics more accurately as focusing exclusively on Hemagen Diagnostics' fundamentals will not take into account other important factors: Hemagen Diagnostics Company Current Valuation Analysis
Hemagen Diagnostics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Hemagen Diagnostics Current Valuation | 441.76 K |
Most of Hemagen Diagnostics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hemagen Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Hemagen Diagnostics has a Current Valuation of 441.76 K. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 99.99% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Hemagen Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hemagen Diagnostics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hemagen Diagnostics could also be used in its relative valuation, which is a method of valuing Hemagen Diagnostics by comparing valuation metrics of similar companies.Hemagen Diagnostics is currently under evaluation in current valuation category among related companies.
Hemagen Fundamentals
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 441.76 K | ||||
| Shares Outstanding | 15.5 M | ||||
| Price To Earning | (0.17) X | ||||
| Price To Sales | 0.1 X | ||||
| Revenue | 4.04 M | ||||
| Gross Profit | 1.61 M | ||||
| EBITDA | (273.66 K) | ||||
| Net Income | (907.32 K) | ||||
| Cash And Equivalents | 66.29 K | ||||
| Current Ratio | 1.07 X | ||||
| Book Value Per Share | (0.23) X | ||||
| Cash Flow From Operations | (358.69 K) | ||||
| Earnings Per Share | (0.06) X | ||||
| Number Of Employees | 15 | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 387.51 K | ||||
| Total Asset | 2.44 M | ||||
| Retained Earnings | (26.68 M) | ||||
| Working Capital | 145 K | ||||
| Current Asset | 2.1 M | ||||
| Current Liabilities | 1.95 M | ||||
| Z Score | -13.0 | ||||
| Net Asset | 2.44 M |
About Hemagen Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hemagen Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hemagen Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hemagen Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Hemagen Diagnostics information on this page should be used as a complementary analysis to other Hemagen Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Hemagen Pink Sheet
If you are still planning to invest in Hemagen Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hemagen Diagnostics' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Directory Find actively traded commodities issued by global exchanges |